NCT07156136

Study of IMC-P115C in Advanced PRAME-Positive Cancers

A Phase 1 First-in-Human Study of the Safety and Efficacy of IMC-P115C as a Single Agent and in Combination With Standard of Care Agents in HLA-A*02:01 Positive Participants With Advanced PRAME Positive Cancers

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 140 (estimated)
• Sponsor: Immunocore Ltd · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Phase 1 First-in-human study of the safety and efficacy of IMC-P115C as a single agent and in combination with standard of care (SOC) agents in participants with advanced PRAME positive cancers. IMC-P115C is a half-life extended (HLE) ImmTAC targeting PRAME.

Conditions

• PRAME Positive
• Cancer
• HLA-A*02:01-positive

Interventions

Type	Name	Description
DRUG	IMC-P115C	IV infusion

Timeline

• Start date: 2024-11-07
• Primary completion: 2027-09-30
• Completion: 2029-08-30
• First posted: 2025-09-04
• Last updated: 2026-02-25

Locations

13 sites across 4 countries: Australia, France, Italy, Spain